Update shared on17 Sep 2025
Fair value Decreased 0.69%Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38.
What's in the News
- Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.
- Completed repurchase of 5,091,156 shares (0.73% of shares) for $94.17 million under July 2024 buyback plan.
- Added to the Russell 1000 Value-Defensive Index.
- Added to the Russell 1000 Defensive Index.
Valuation Changes
Summary of Valuation Changes for Healthpeak Properties
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $21.53 to $21.38.
- The Future P/E for Healthpeak Properties remained effectively unchanged, moving only marginally from 95.43x to 93.78x.
- The Net Profit Margin for Healthpeak Properties remained effectively unchanged, moving only marginally from 6.50% to 6.42%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.